Skip to main content Skip to section navigation Skip to footer
Virax Biolabs Group Limited
  • Our Platforms
    • ViraxImmune™
    • ViraxClear™
    • ViraxVet™
  • Our Focus
    • T-Cell Testing
    • In Vitro Diagnostics
  • Resources
    • Investor Relations
    • Media Room
    • Blog
    • Events
  • About Us
    • Our Team
    • Careers
    • Partnership
    • Contact Us
Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix

Press Releases

  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Sep 12, 2023 7:30am EDT

Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar

Sep 01, 2023 7:30am EDT

Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum

Aug 03, 2023 7:30am EDT

Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid

Jul 18, 2023 7:30am EDT

Virax Biolabs Group Continues Growth and Expansion with the Addition of Research and Laboratory Facilities

Jun 14, 2023 7:30am EDT

Virax Biolabs' CEO James Foster Issues Letter to Shareholders

May 04, 2023 7:30am EDT

Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science Park

Apr 19, 2023 7:30am EDT

Virax Biolabs Group Limited Has Entered into an Agreement for the Distribution of Marburg Virus PCR Testing Kits

Mar 10, 2023 5:17pm EST

Virax Biolabs Group Limited Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Mar 08, 2023 8:55am EST

Virax Biolabs Group Limited Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Mar 07, 2023 7:30am EST

Virax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test Kit

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Virax Biolabs Group Limited
20 North Audley Street
London
W1K 6LX
United Kingdom
Our Platforms
  • Virax Immune
  • ViraxClear
Our Focus
  • T-Cell Testing
  • In Vitro Diagnostics
Resources
  • Media Room
  • Events
  • Investor Relations
About Us
  • Our Team
  • Careers
  • Partnership
  • Contact Us
Twitter  /  Facebook  /  LinkedIn  /  Instagram

© All Rights Reserved, Virax Biolabs 2023 | Privacy Policy | Terms of Service